Studies demonstrated that targeting the CCL2/CCR2 axis with the antibody carlumab (CNTO 888) as well as with a specific inhibitor of the CCR2 receptor (PF-04136309) specifically blocks the CCL2-mediated activation and migration of macrophages into tumors and tumor’s infiltration by macrophages in patients with diverse types of cancers (149). This evidence concerns the gene CCR2 and neoplasm.